Nektar Therapeutics
NKTRNektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Drugs in Pipeline
13
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How NKTR's past catalysts played out
Rezpegaldesleukin
Moderate to Severe Atopic Dermatitis
Treatment of Physician's Choice (TPC)
Locally Recurrent Breast Cancer
NKTR-181 BID tablets
Low Back Pain
Eribulin
Metastasis
NKTR-102
Tumor
NKTR-214
Unspecified Adult Solid Tumor, Protocol Specific
NKTR-255
Head and Neck Squamous Cell Carcinoma
NKTR-102 145 mg/m2
Malignant Solid Tumor
NKTR-102 100 mg/m2
Tumor
Bempegaldesleukin
Urinary Bladder Neoplasm
LY3471851
Systemic Lupus Erythematosus
NKTR-102 q14d
Tumor
NKTR-181
Osteoarthritis of the Knee
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rezpegaldesleukin | Phase 3 | Moderate to Severe Atopic Dermatitis | - | - |
Treatment of Physician's Choice (TPC) | Phase 3 | Locally Recurrent Breast Cancer | - | - |
NKTR-181 BID tablets | Phase 3 | Low Back Pain | - | - |
Eribulin | Phase 3 | Metastasis | - | - |
NKTR-102 | Phase 3 | Tumor | - | - |
NKTR-214 | Phase 2 | Unspecified Adult Solid Tumor, Protocol Specific | - | - |
NKTR-255 | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
NKTR-102 145 mg/m2 | Phase 2 | Malignant Solid Tumor | - | - |
NKTR-102 100 mg/m2 | Phase 2 | Tumor | - | - |
Bempegaldesleukin | Phase 2 | Urinary Bladder Neoplasm | - | - |
LY3471851 | Phase 2 | Systemic Lupus Erythematosus | - | - |
NKTR-102 q14d | Phase 2 | Tumor | - | - |
NKTR-181 | Phase 2 | Osteoarthritis of the Knee | - | - |
Unspecified Adult Solid Tumor, Protocol Specific
1 drug in this indication
Urinary Bladder Neoplasm
1 drug in this indication
Moderate to Severe Atopic Dermatitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Nektar Therapeutics's drug pipeline?→
CatalystAlert tracks 13 drug candidates in Nektar Therapeutics's (NKTR) pipeline across Phase 3, Phase 2. Its lead program is Rezpegaldesleukin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nektar Therapeutics's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Nektar Therapeutics (NKTR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NKTR biotech catalysts?→
Add NKTR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nektar Therapeutics's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.